Equity Research Analysis: GH Research PLC (GHRS)
|Blank Capital Research Unit|Spot: $15.27
Price$15.27
Composite Score35.9/100
RatingAVOID (1★)
Rank#4019 OF 7,333
Market Cap$364M
ROE
Intelligence Feed
yahoo6d ago Positive
RBC Capital Cite GH Research PLC’s (GHRS) Long-Term Sales Potential Following Psychedelics Symposium
GH Research PLC (NASDAQ:GHRS) is among the 7 Most Promising Psychedelic Stocks According to Hedge Funds. GH Research PLC (NASDAQ:GHRS) is placed sixth on our list. TheFly reported that on January 23, RBC Capital raised its price target on GHRS to $40 from $33 and maintained an Outperform rating. RBC stated that it was growing […]
simplywall.stJan 8 Positive
Assessing GH Research (GHRS) Valuation After FDA Lifts Clinical Hold On GH001 IND
GH Research (NasdaqGM:GHRS) is back in focus after the U.S. Food and Drug Administration lifted the clinical hold on its GH001 IND, clearing the way for U.S. enrollment in treatment-resistant depression trials. See our latest analysis for GH Research. The FDA decision appears to have been a key catalyst, with a 1 day share price return of 27.12% and a 7 day share price return of 41.34% lifting the stock to $17.95. At the same time, the 1 year total shareholder return of 99.89% and 3 year...
BenzingaJan 5 Neutral
Stock Market Today: S&P 500, Nasdaq, WTI Crude Futures Advance After US Strike On Venezuela— GH Research, Vertiv Holdings, Nukkleus In Focus (UPDATED)
U.S. stock futures rose on Monday as major indices opened the first full trading week of 2026 higher. Following the U.S. strike on Venezuela and removal of President Maduro, crude oil prices fluctuated around $57.29 per barrel. Several stocks gained attention: Vertiv Holdings jumped on an upgrade, GH Research soared on FDA update news, Nukkleus rose after acquiring Israeli defense software, Ironwood advanced on positive FY26 guidance, and Brand Engagement Network climbed on a new vendor agreement. JPMorgan's outlook suggests continued but challenged strength in U.S. equities, with potential 10-15% corrections offset by year-end gains driven by AI-related spending.
yahoo6d ago Negative
Psychedelics stocks rise as Compass’ psilocybin drug heads to FDA
Shares of at least four other developers were up by mid-single digits to low-double digits at certain points on Tuesday.
simplywall.stJan 16 Negative
GH Research (GHRS) Is Up 9.1% After FDA Lifts Clinical Hold On GH001 Depression Drug
GH Research PLC recently reported that the U.S. Food and Drug Administration lifted the clinical hold on its GH001 investigational new drug application, allowing U.S. subject enrollment following Phase 2b data in treatment-resistant depression showing a 15.5-point placebo-adjusted MADRS score reduction by Day 8, high remission rates with infrequent dosing, brief psychoactive sessions, and no serious treatment-related adverse events. This combination of rapid symptom relief, minimal treatment...